论文部分内容阅读
目的:探讨利金方对慢性阻塞性肺疾病(COPD)肺气虚证大鼠血清和支气管肺泡灌洗液(BALF)中白三烯B4(LTB4)的表达及气道炎症的影响。方法:将50只SPF级Wistar大鼠随机分为5组:空白组、模型组、补肺汤组、利金方低剂量组、利金方高剂量组。采用复合因素造模法建立COPD大鼠模型。各药物组分别以相应剂量连续给药14天。14天后检测各组大鼠血清和BALF中LTB4的含量,并比较各组小气道炎症积分情况。结果:模型组小气道炎症积分、血清及BALF中LTB4的含量明显升高;与模型组比较,应用利金方、补肺汤干预后,小气道炎症积分、血清及BALF中LTB4的含量明显下降,差异有统计学意义(P<0.05);利金方高剂量组与补肺汤组比较,小气道炎症积分、血清及BALF中LTB4的含量下降也有显著性差异(P<0.05)。结论:LTB4在COPD气道炎症中起重要作用,利金方对气道炎症有抑制作用,其机制与抑制血清及BALF中LTB4的表达有关。
Objective: To investigate the effect of Li Jinfang on leukotriene B4 (LTB4) expression and airway inflammation in serum and bronchoalveolar lavage fluid (BALF) in rats with chronic obstructive pulmonary disease (COPD). Methods: Fifty SPF Wistar rats were randomly divided into five groups: blank group, model group, Bufei Decoction group, Lijinfang low-dose group and Lijinfang high-dose group. The COPD rat model was established using a composite factor model. Each drug group was continuously administered for 14 days at the corresponding dose. After 14 days, the serum and LTB4 levels in BALF were measured in each group, and the scores of small airway inflammation in each group were compared. RESULTS: In the model group, small airway inflammation scores, serum and LTB4 levels in BALF were significantly increased. Compared with the model group, the use of Lijinfang and Bufei Decoction significantly decreased the scores of small airway inflammation, serum and LTB4 in BALF. The difference was statistically significant (P<0.05). Compared with Bufei Decoction group, the high-dose Lijinfang group had significantly lower inflammation scores, serum and BALF LTB4 content (P<0.05). Conclusion: LTB4 plays an important role in COPD airway inflammation. Lijinfang can inhibit airway inflammation. Its mechanism is related to the inhibition of serum and LTB4 expression in BALF.